Real TimePCR and melting curve analysis were done as described before 58
Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development
She is a fitness freak, who takes good care of her body and skin
10.3389/fmolb.2018.00008 187 KonopkaA.AtkinJ
Disclosures: Fajuan Rui: Nothing to Disclose, Yee Hui Yeo: Nothing to Disclose, Wenjing Ni: Nothing to Disclose, Liang Xu: Nothing to Disclose, Qi Zheng: Nothing to Disclose, Youwen Tan: Nothing to Disclose, Qing-Lei Zeng: Nothing to Disclose, Ming-Hua Zheng: Nothing to Disclose, Zebao He: Nothing to Disclose, Yuanwang Qiu: Nothing to Disclose, chuanwu zhu: Nothing to Disclose, Chao Wu: Nothing to Disclose, Yuemin Nan: Nothing to Disclose, Junping Shi: Nothing to Disclose, Jie Li: Nothing to Disclose 427 CHARACTERIZATION OF HDV RNA AND HBSAG DURING PEGYLATED INTERFERON-ALPHA AND RITONAVIR-BOOSTED LONAFARNIB COMBINATION THERAPY: THE D-LIVR STUDY Leeor Hershkovich 1 Harel Dahari 1 Scott Cotler 2 Theo Heller 3 Christopher Koh 3 Jeffrey Glenn 4 Tarik Asselah 5 Saeed Hamid 6 Ohad Etzion 7 , 1 Loyola University Chicago, 2 Loyola University Health System, 3 Liver Disease Branch, NIDDK, NIH, 4 Stanford School of Medicine, 5 Hpital Beaujon, 6 Aga Khan University, 7 Soroka University Medical Center Background: Understanding of the kinetic profiles of hepatitis D virus (HDV) and hepatitis B surface antigen (HBsAg) during pegylated-interferon--2a (pegIFN) and ritonavir-boosted lonafarnib (LNF) therapy is lacking
